In-house Discovery

In addition to its serviced-based operation, Prosarix is using the ProtoDiscovery™ platform to develop a limited number of lead series against specific GPCR targets which have application in the CNS field.

Prosarix's most advanced program has recently shown pre-clinical efficacy in models of pain, anxiety and depression.

Please contact Prosarix for further information/register your interest:


©Prosarix 2007-2020

℅ RxCelerate Ltd, Moneta B280, Babraham Research Park, Cambridge, CB22 3AT ¦ +44 (0)1223 839557 ¦ ¦ legal